P567 Budesonide induces clinical remission and improves quality of life in active collagenous colitis: results from the open-label induction phase of BUC-63/COC

Münch, Andreas; Bohr, Johan; Benoni, Cecilia; Olesen, Martin; Öst, Åke; Hjortswang, Henrik; Hellström, P. M.; Strandberg, Linn; Björk, Jan; Hertervig, Erik; Lindberg, Greger; Lapidus, Annika; Löfberg, Robert; Miehlke, Stephan; Kirsch, Christian; Armerding, Peter; Bonderup, Ole K.; Stehlík, J; Müller, R.; Greinwald, Roland; Tysk, Curt; Ström, M.

doi:10.1016/s1873-9946(13)60588-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Fazit Und Ausblick1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2013

2021

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Steroid-refractory patients account for 10%-20% of CC individuals included in clinical trials and represent a clinical challenge. [47][48][49][50] In fact, no previous pathological characterization of aRCC has been reported to date. Despite the resemblance of aRCC transcriptome with auCC samples, we observed that leukocyte cell adhesion and wound healing processes are similarly altered in aRCC and UC but differ from auCC samples.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease

Escudero-Hernández

Granlund²,

Sandvik³

et al. 2021

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease

Escudero-Hernández

Granlund²,

Sandvik³

et al. 2021

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Eine remissionserhaltende Therapie mit Budesonid 6 mg täglich für 6 Monate ist nach derzeitigem Kenntnisstand effektiv und sicher. Eine gerade abgeschlossene europäische RCT hat die Wirksamkeit von 4,5 mg Budesonid täglich in der Remissionserhaltung über 12 Monate untersucht [44]. Die abschließenden Ergebnisse werden Ende 2013 mit Spannung erwartet.…”

Section: Fazit Und Ausblickunclassified

Mikroskopische Kolitis – neue praxisrelevante Erkenntnisse

2013

Self Cite

View full text Add to dashboard Cite

Microscopic colitis is an increasingly recognised chronic inflammatory bowel disease associated with watery, non-bloody diarrhoea. In addition, many patients suffer from abdominal pain, nocturnal diarrhoea, urgency and incontinence. The two traditional histological subtypes are collagenous colitis and lymphocytic colitis. A novel third subgroup is the so-called incomplete microscopic colitis which is clinically indistinguishable. At present, budesonide is the only evidenced-based effective therapy, however many problems in the long-term treatment strategy are still unsolved. The present paper reviews new developments in microscopic colitis which are relevant for clinical practice.

show abstract

Risk Factors for Symptom Relapse in Collagenous Colitis After Withdrawal of Short-term Budesonide Therapy

Miehlke¹,

Hansen

Madisch³

et al. 2013

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

P567 Budesonide induces clinical remission and improves quality of life in active collagenous colitis: results from the open-label induction phase of BUC-63/COC

Cited by 3 publications

References 0 publications

Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease

Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease

Mikroskopische Kolitis – neue praxisrelevante Erkenntnisse

Risk Factors for Symptom Relapse in Collagenous Colitis After Withdrawal of Short-term Budesonide Therapy

Contact Info

Product

Resources

About